Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Immatics Announces Pricing of $175 Million Public Offering
08:30pm, Wednesday, 17'th Jan 2024
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-r
Immatics Announces Proposed Public Offering
04:01pm, Wednesday, 17'th Jan 2024
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-
Immatics Announces Third Quarter 2023 Financial Results and Business Update
07:00am, Tuesday, 14'th Nov 2023
Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-red
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
07:00am, Wednesday, 08'th Nov 2023
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
09:47am, Monday, 06'th Nov 2023
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
07:00am, Tuesday, 24'th Oct 2023
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)
11:18am, Thursday, 12'th Oct 2023
Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Analyzing Immatics' Multi-Faceted Investment Case
01:33am, Monday, 09'th Oct 2023
Immatics showcases a robust financial position and promising IMA203 TCR-T cell therapy for oncology with impressive safety and efficacy data. Risks include high competition in T-cell therapies, potent
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
06:50am, Tuesday, 12'th Sep 2023
Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX)
Immatics inks deal worth $120M to $1.7B with Moderna to boost cancer vaccine development
11:31am, Monday, 11'th Sep 2023
Immatics NV's shares rose Monday after it announced a collaboration with Moderna Therapeutics Inc (NASDAQ:MRNA) to pioneer novel and transformative therapies for cancer patients with high unmet medic
Immatics shares rise on Moderna cancer collaboration
08:59am, Monday, 11'th Sep 2023
Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The par
Moderna, Immatics to work jointly on cancer vaccines
07:32am, Monday, 11'th Sep 2023
Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
07:00am, Monday, 11'th Sep 2023
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna'
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%
11:16am, Monday, 21'st Aug 2023
The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
09:31am, Thursday, 17'th Aug 2023
Immatics (IMTX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.23 per share a year ago.
